Trials / Terminated
TerminatedNCT05866926
Study to Investigate the Long-term Safety of FAB122 in Patients With Amyotrophic Lateral Sclerosis
A Multicenter, Open-label Extension Study to Investigate the Long-term Safety of FAB122 in Patients With Amyotrophic Lateral Sclerosis
- Status
- Terminated
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 201 (actual)
- Sponsor
- Ferrer Internacional S.A. · Industry
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
A multicenter, open-label extension study to investigate the long-term safety of FAB122 in patients with Amyotrophic Lateral Sclerosis
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | FAB122 | FAB122 Daily dose 100 mg |
Timeline
- Start date
- 2023-03-06
- Primary completion
- 2024-01-09
- Completion
- 2024-02-22
- First posted
- 2023-05-19
- Last updated
- 2025-03-04
- Results posted
- 2025-03-04
Locations
1 site across 1 country: Spain
Source: ClinicalTrials.gov record NCT05866926. Inclusion in this directory is not an endorsement.